Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$102.28 USD

102.28
1,423,155

-2.40 (-2.29%)

Updated Oct 7, 2024 04:00 PM ET

After-Market: $102.80 +0.52 (0.51%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.

Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.

AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.

ZBH vs. LMAT: Which Stock Is the Better Value Option?

by Zacks Equity Research

ZBH vs. LMAT: Which Stock Is the Better Value Option?

QuidelOrtho (QDEL) Down 4.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Buy Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on ongoing business recovery.

Zimmer Biomet (ZBH) Gains From Market Recovery, Global Growth

by Zacks Equity Research

Zimmer Biomet (ZBH) witnesses continued traction across hip products, including the G7 revision system and Avenir Complete primary hip.

ZBH vs. LMAT: Which Stock Is the Better Value Option?

by Zacks Equity Research

ZBH vs. LMAT: Which Stock Is the Better Value Option?

Zacks Industry Outlook Highlights Stryker, Zimmer Biomet and Haemonetics

by Zacks Equity Research

Stryker, Zimmer Biomet and Haemonetics have been highlighted in this Industry Outlook article.

Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, ZBH and HAE are well-poised to gain from the favorable factors.

STAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.

Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.

Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 2.73% and 3.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?

by Zacks Equity Research

Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.

ZBH vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

ZBH vs. ABT: Which Stock Is the Better Value Option?

BellRing Brands (BRBR) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have witnessed continued recovery in its legacy business in the fourth quarter, despite the choppy market situation.

Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.

Zimmer Biomet (ZBH) Procedure Volume Gain Aids Amid FX Hurdles

by Zacks Equity Research

Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.